Dr. Martina RossiPhDIpamorelin is a synthetic pentapeptide growth hormone secretagogue investigated in published research for its selective interaction with the GHS-R1a receptor in the context of growth hormone signalling. It was developed by Novo Nordisk as a drug candidate — Raun et al. concluded that its specificity made it a very interesting candidate for future clinical development — and studies noted a more selective endocrine signalling profile than earlier GHRPs such as GHRP-6. Preclinical studies have examined dose-dependent growth hormone secretion patterns in animal models.
Research on Ipamorelin has proven important for investigating growth hormone (GH) regulation, given its specific design. So, what is Ipamorelin? Ipamorelin is a synthetic pentapeptide growth hormone-releasing peptide (GHRP) that works as a specific GHS-R1a receptor agonist, similar to ghrelin. The intriguing aspect of Ipamorelin's background is that it can release GH, whereas earlier GHRPs could not do so without accompanying side hormonal effects. This article explains the Ipamorelin peptide structure, its mechanism of action, what makes it a selective secretagogue compared with older GHRPs such as GHRP-6, and what the preclinical literature actually shows. Ipamorelin is a research compound and is not characterized for human use here.
Ipamorelin is a small synthetic peptide, and its position in the field can best be understood when compared to the previous compounds. Growth hormone-releasing peptides were first described by Bowers et al. in 1980 (Endocrinology 106(3):663-7; PubMed PMID: 7353536). Their 1984 publication[1] reported that a new synthetic hexapeptide, called GHRP-6, could release GH from the pituitary gland via an unidentified mechanism independent of GHRH. GHRP-6 was potent but not a clean probe of the GH axis: Bowers et al. reported GH release without any concomitant rise in LH, FSH, TSH or PRL and did not report ACTH or cortisol, and later work in conscious swine showed that GHRP-6 also raised plasma ACTH and cortisol (Raun et al.[2]). Ipamorelin was identified in a chemistry programme screening compounds that lacked the central Ala-Trp dipeptide of GHRP-1, and its failure to raise ACTH and cortisol was an unexpected finding rather than a designed outcome; according to Raun et al.'s[2] 1998 work, it was nonetheless the first example of a selective growth hormone secretagogue of this kind.
The Ipamorelin peptide structure is a pentapeptide, written as Aib-His-D-2-Nal-D-Phe-Lys-NH2, where Aib is the non-natural residue alpha-aminoisobutyric acid, and D-2-Nal is a D-configuration naphthylalanine. The use of non-natural and D-amino acids, together with the C-terminal amide, is what gives the molecule its metabolic stability. Its endocrine selectivity is not explained by binding a different receptor: antagonist profiling by Raun et al.[2] showed that ipamorelin, like GHRP-6, releases GH via the same GHRP-like receptor, and those authors described the absence of an ACTH and cortisol response as very surprising rather than designed. It is a fully synthetic construct that does not correspond to any natural peptide sequence.
The mode of action of Ipamorelin involves a distinct pathway and receptor compared to the GHRH receptor. This receptor, the GHS-R1a, was first discovered by Howard et al.[3] in 1996 and was found to function as a pituitary and hypothalamic receptor in regulating growth hormone release; however, its endogenous ligand had not yet been identified. It was not until 1999 that Kojima et al.[4] discovered ghrelin, the acylated peptide, which led to the identification of GHS-R1a as the ghrelin receptor, thereby classifying the GHRPs as ghrelin agonists or analogs. In binding with GHS-R1a receptors in the somatotrophs of the pituitary gland, Ipamorelin acts to induce GH secretion by activating the signal transduction pathways without using the cAMP-dependent mechanism employed by GHRH-class secretagogues. As both pathways are distinct yet interconnected, the two types of secretagogues are often studied together.
This is the heart of the Ipamorelin versus GHRP-6 comparison. In the same studies that established its GH-releasing potency, Raun et al.[2] showed that Ipamorelin released GH with potency and efficacy comparable to GHRP-6, but that in conscious swine — where both GHRP-6 and GHRP-2 raised plasma ACTH and cortisol — ipamorelin produced ACTH and cortisol levels not significantly different from those following GHRH stimulation, even at doses more than 200-fold above its ED50 for GH release. This is precisely what has made this compound selective: it acts on the GH axis via GHS-R1a without the ACTH and cortisol rise that GHRP-6 and GHRP-2 produced in the same study; in that study none of the secretagogues tested, ipamorelin included, altered FSH, LH, PRL or TSH. For anyone studying GH biology, a probe that moves GH without simultaneously moving cortisol is a cleaner instrument, and that selectivity is the single most cited feature of the molecule.
The Ipamorelin preclinical studies are where the body of evidence sits. The foundational animal pharmacology study by Raun et al.[2] characterized GH release in rat pituitary cells in vitro, in anaesthetised rats and in conscious swine; the hormone-specificity work that defines the compound, including the ACTH and cortisol measurements, was carried out only in the swine. In addition to being studied for its fundamental characteristics, the peptide has served as a research tool in specific physiological models. Andersen et al.[5] reported in 2001 that in adult rats, Ipamorelin counteracted a glucocorticoid-induced decrease in bone formation, in a study examining the GH axis in the context of corticosteroid effects on bone. Separately, Venkova et al.[6] used Ipamorelin as a ghrelin mimetic in a rat model of postoperative ileus in 2009, reporting that a single dose shortened the time to first bowel movement without changing cumulative fecal output, food intake, or weight gain, while repeated dosing increased all three. Together, these illustrate how the molecule has been deployed across distinct preclinical questions, all in animal or cellular systems, and none predicting an outcome in people.
Human research on Ipamorelin is minimal and should be read as separate from the animal work. Two studies in humans have been published. An early-phase pharmacokinetic-pharmacodynamic study in healthy male volunteers characterised how the peptide behaves in the body and its GH response across five infusion rates (Gobburu et al., Pharm Res 1999; PubMed PMID: 10496658). Ipamorelin was then taken into clinical development for postoperative ileus: a phase 2, multicentre, randomised, double-blind, placebo-controlled trial (NCT00672074) in 114 bowel-resection patients found it well tolerated but no better than placebo on the key efficacy endpoint, median time to tolerating a standardised solid meal (25.3 h vs 32.6 h, p = 0.15), or on the secondary efficacy analyses (Beck et al., Int J Colorectal Dis 2014;29(12):1527-34; PubMed PMID: 25331030). There is no approved use, and almost everything else known about the compound comes from preclinical pharmacology. Any extrapolation from this limited human data to a real-world outcome is unsupported.
Studies on Ipamorelin have several limitations to consider when interpreting the results. There is no approved use, and the compound is not characterized for human use. Much of the defining preclinical work comes from the original developer, which raises the usual question of independent replication, and the long-term effects of GHS-R1a receptor stimulation are not well characterized. As with any research peptide, the identity and purity of the material vary across sources, which matters for any laboratory study using research-grade Ipamorelin. Taking all this into account, the mechanism is well defined and the selectivity is its genuine distinction, though it rests on that single unreplicated developer study, but the broader evidence base remains limited and the open questions are mostly those that properly controlled studies have not yet answered.
Ipamorelin is a selective, synthetic ghrelin receptor agonist: a stable pentapeptide that acts at GHS-R1a to release growth hormone while sparing the ACTH and cortisol responses that complicated earlier GHRPs such as GHRP-6. The preclinical pharmacology that defines it is coherent, but its selectivity rests on a single set of swine experiments from the original developer and has not been independently replicated, and the broader evidence base is limited with no approved indication. Material referenced here is intended for laboratory research use only, and the findings describe what has been studied in preclinical systems, not what any individual should expect.
Ipamorelin is available for laboratory research from Pure Peptides. View Product →
References
WRITTEN BY
Dr. Martina Rossi
PhD — Scientific Contributor and Reviewer
Dr. Martina Rossi holds a PhD from Universite Grenoble Alpes, where her doctoral research examined the vascular functions of Bone Morphogenetic Proteins in knockout mouse models. Her published work spans cell and molecular biology, vascular biology, and gene therapy, with peer-reviewed contributions appearing in journals including Cardiovascular Research, Scientific Reports, and Brain Sciences. Dr. Rossi serves as Scientific Contributor and Reviewer for the Pure Peptides research content program, independently reviewing articles for scientific accuracy.
View team profile →
An evidence-based overview of CJC-1295 research: its modified GHRH analog structure, the Drug Affinity Complex mechanism, and what preclinical studies show about GH and IGF-1 signaling.
